Monte Rosa to launch Phase 2 trial of MRT-2359 plus apalutamide in AR-mutant mCRPC in Q3 2026

Reuters

Mar 16

Monte Rosa to launch Phase 2 trial of MRT-2359 plus apalutamide in AR-mutant mCRPC in Q3 2026

Monte Rosa said it entered a clinical supply agreement with Johnson & Johnson to support a planned Phase 2 trial of MRT-2359 in combination with apalutamide (ERLEADA) for metastatic castration-resistant prostate cancer patients with androgen receptor mutations. The company expects the study to start in Q3 2026 and enroll up to 25 patients. Endpoints include PSA response, RECIST response, duration of response, progression-free survival, radiographic progression-free survival, and safety. Monte Rosa will sponsor and conduct the trial, while Johnson & Johnson will supply ERLEADA. Results from an ongoing Phase 1/2 study of MRT-2359 plus enzalutamide were previously presented at the 2026 ASCO GU Cancers Symposium.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monte Rosa Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603160700PRIMZONEFULLFEED9672321) on March 16, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2619529634"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2619529634\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2619529634?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-16 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2619529634","market":"nz","top_or_hot":-1,"title":"Monte Rosa to launch Phase 2 trial of MRT-2359 plus apalutamide in AR-mutant mCRPC in Q3 2026","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Monte Rosa to launch Phase 2 trial of MRT-2359 plus apalutamide in AR-mutant mCRPC in Q3 2026\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Monte Rosa said it entered a clinical supply agreement with Johnson &amp; Johnson to support a planned Phase 2 trial of MRT-2359 in combination with apalutamide (ERLEADA) for metastatic castration-resistant prostate cancer patients with androgen receptor mutations. The company expects the study to start in Q3 2026 and enroll up to 25 patients. Endpoints include PSA response, RECIST response, duration of response, progression-free survival, radiographic progression-free survival, and safety. Monte Rosa will sponsor and conduct the trial, while Johnson &amp; Johnson will supply ERLEADA. Results from an ongoing Phase 1/2 study of MRT-2359 plus enzalutamide were previously presented at the 2026 ASCO GU Cancers Symposium.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/GLUE\">Monte Rosa Therapeutics</a> Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603160700PRIMZONEFULLFEED9672321) on March 16, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Monte Rosa to launch Phase 2 trial of MRT-2359 plus apalutamide in AR-mutant mCRPC in Q3 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMonte Rosa to launch Phase 2 trial of MRT-2359 plus apalutamide in AR-mutant mCRPC in Q3 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-16 19:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Monte Rosa to launch Phase 2 trial of MRT-2359 plus apalutamide in AR-mutant mCRPC in Q3 2026\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Monte Rosa said it entered a clinical supply agreement with Johnson &amp; Johnson to support a planned Phase 2 trial of MRT-2359 in combination with apalutamide (ERLEADA) for metastatic castration-resistant prostate cancer patients with androgen receptor mutations. The company expects the study to start in Q3 2026 and enroll up to 25 patients. Endpoints include PSA response, RECIST response, duration of response, progression-free survival, radiographic progression-free survival, and safety. Monte Rosa will sponsor and conduct the trial, while Johnson &amp; Johnson will supply ERLEADA. Results from an ongoing Phase 1/2 study of MRT-2359 plus enzalutamide were previously presented at the 2026 ASCO GU Cancers Symposium.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/GLUE\">Monte Rosa Therapeutics</a> Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603160700PRIMZONEFULLFEED9672321) on March 16, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nNDLc9b2n1:1","article_id":"2619529634","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2619529634","pubTimestamp":1773658849,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Monte Rosa said it entered a clinical supply agreement with Johnson & Johnson to support a planned Phase 2 trial of MRT-2359 in combination with apalutamide  for metastatic castration-resistant prostate cancer patients with androgen receptor mutations. The company expects the study to start in Q3 2026 and enroll up to 25 patients. Endpoints include PSA response, RECIST response, duration of response, progression-free survival, radiographic progression-free survival, and safety. Monte Rosa will sponsor and conduct the trial, while Johnson & Johnson will supply ERLEADA. Results from an ongoing Phase 1/2 study of MRT-2359 plus enzalutamide were previously presented at the 2026 ASCO GU Cancers Symposium.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","IE00BN8TJ469.HKD":"FTGF CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A\" (HKD) INC","LU0795875086.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","NDAQ":"纳斯达克OMX交易所","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","LU1032466523.USD":"高盛全球多资产收益组合Acc","LU2471134523.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) ACC","LU2129689605.HKD":"FRANKLIN GLOBAL INCOME \"A\" (HKD) INC","BK4581":"高盛持仓","LU1929549753.HKD":"FRANKLIN INCOME \"A\" (HKD) INC","LU0234572021.USD":"高盛美国核心股票组合Acc","LU1221951046.USD":"NORDEA 1 STABLE RETURN \"HM\" (USDHDG) INC","LU2129689431.USD":"FRANKLIN GLOBAL INCOME \"A\" (USD) ACC","LU1032955483.USD":"NORDEA 1 STABLE RETURN \"HB\" (USDHDG) ACC","LU2471134952.CNY":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (CNYHDG) INC","IE00B42XCP33.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) INC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","JNJ":"强生","LU0792757196.USD":"TEMPLETON SHARIAH GLOBAL EQUITY FUND \"A\" (USD) ACC","IE00BN0W2W23.USD":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","IE00BN0W2V16.EUR":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","LU1732799900.SGD":"JPMorgan Investment Funds - Global Income A (irc) SGD-H","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU2505996681.GBP":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4H\" (GBPHDG) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU1059921491.USD":"NORDEA 1 GLOBAL STABLE EQUITY \"HB\" (USDHDG) ACC","GLUE":"Monte Rosa Therapeutics","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","SG9999002232.USD":"Allianz Global High Payout USD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00BVYPNV92.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","LU0985320562.USD":"NORDEA 1 GLOBAL STARS EQUITY \"BP\" (USD) ACC","IE0034235303.USD":"PINEBRIDGE US RESEARCH ENHANCED CORE EQUITY \"A\" (USD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1066051811.HKD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (HKD) INC"},"translate_title":"Monte Rosa将于2026年第三季度启动MRT-2359联合apalutamide治疗AR突变型mCRPC的2期试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GLUE":0.9,"NDAQ":0.9,"JNJ":0.9},"content_text":"Monte Rosa to launch Phase 2 trial of MRT-2359 plus apalutamide in AR-mutant mCRPC in Q3 2026\n    \n\n        Monte Rosa said it entered a clinical supply agreement with Johnson & Johnson to support a planned Phase 2 trial of MRT-2359 in combination with apalutamide (ERLEADA) for metastatic castration-resistant prostate cancer patients with androgen receptor mutations. The company expects the study to start in Q3 2026 and enroll up to 25 patients. Endpoints include PSA response, RECIST response, duration of response, progression-free survival, radiographic progression-free survival, and safety. Monte Rosa will sponsor and conduct the trial, while Johnson & Johnson will supply ERLEADA. Results from an ongoing Phase 1/2 study of MRT-2359 plus enzalutamide were previously presented at the 2026 ASCO GU Cancers Symposium.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monte Rosa Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603160700PRIMZONEFULLFEED9672321) on March 16, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}